LOG IN
SIGN UP
MARKET
CGEN
CGEN
Compugen
NASDAQ
Real-time Quotes | Nasdaq Last Sale
1.870
+0.170
+10.00%
After Hours: 1.930 +0.06 +3.21% 19:17 05/27 EDT
OPEN
1.720
PREV CLOSE
1.700
HIGH
1.925
LOW
1.681
VOLUME
1.32M
TURNOVER
0
52 WEEK HIGH
9.20
52 WEEK LOW
1.660
MARKET CAP
161.63M
P/E (TTM)
-4.6727
1D
5D
1M
3M
1Y
5Y
BRIEF-Compugen Reports Q1 Loss Of 11 Cents Per Share
reuters.com · 05/16 11:47
Recap: Compugen Q1 Earnings
Compugen (NASDAQ:CGEN) reported its Q1 earnings results on Monday, May 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/16 11:33
CORRECTION: Compugen Q1 EPS $(0.11) Beats $(0.13) Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.13) by 15.38 percent. This is a 8.33 percent increase over losses of $(0.12) per share from the same
Benzinga · 05/16 11:19
Compugen GAAP EPS of -$0.11 beats by $0.01
Compugen press release (NASDAQ:CGEN): Q1 GAAP EPS of -$0.11 beats by $0.01. Cash balance of $107M affirms focus on capital efficiency with bold execution on Compugen's DNAM-1 axis hypothesis. The
Seekingalpha · 05/16 11:06
Compugen Reports First Quarter 2022 Results
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today financial results for the first quarter ended March 31, 2022 and provided a corporate update on key events since th...
PR Newswire · 05/16 11:00
Compugen Q1 EPS $(0.27) Misses $(0.13) Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.13) by 107.69 percent. This is a 125 percent decrease over losses of $(0.12) per share from the
Benzinga · 05/16 10:47
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Benzinga · 05/16 09:18
-- Earnings Flash (CGEN) COMPUGEN Posts Q1 Loss $-0.11, vs. Street Est of $-0.12
MT Newswires · 05/16 07:07
No Data
Learn about the latest financial forecast of CGEN. Analyze the recent business situations of Compugen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 7 analysts
Strong Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
57.14%Strong Buy
42.86%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CGEN stock price target is 11.75 with a high estimate of 14.00 and a low estimate of 8.00.
Current 1.870
EPS
Actual
Estimate
-0.11-0.08-0.06-0.03
Institutional Holdings
Institutions: 131
Institutional Holdings: 42.15M
% Owned: 48.77%
Shares Outstanding: 86.43M
TypeInstitutionsShares
Increased
33
2.93M
New
14
7.19M
Decreased
30
1.23M
Sold Out
19
954.79K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Paul Sekhri
President/Chief Executive Officer/Director
Anat Cohen-Dayag
Chief Financial Officer/Chief Operating Officer
Ari Krashin
Senior Vice President
Henry Adewoye
Senior Vice President
Oliver Froescheis
Senior Vice President
Zurit Levine
Senior Vice President
Yaron Turpaz
Independent Director
Jean-Pierre Bizzari
Independent Director
Gilead Halevy
Independent Director
Kinneret Livnat Savitsky
Independent Director
Eran Perry
Independent Director
Sanford Zweifach
No Data
No Data
About CGEN
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Webull offers kinds of Compugen Ltd. (USA) stock information, including NASDAQ:CGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEN stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading CGEN stock methods without spending real money on the virtual paper trading platform.